Skip to content

Study · Non-randomized trial · n = 13 · 2003

6 results

GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.

Martins MR, Pinto AC, Brunner E, Silva MR, Lengyel AM

Journal of endocrinological investigation1 Feb 2003Cited by 1 (Europe PMC)

PMID12739742 (opens in a new tab)DOI10.1007/bf03345143 (opens in a new tab)PepBankPUB-12739742
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    Patients with Addison's disease on replacement had a significantly higher ACTH response to GHRP‑6 than control subjects.

    In plain wordsPeople with Addison's disease on replacement had a bigger ACTH rise after GHRP‑6 than control people.

    Peptide
    GHRP-6
    Outcome
    IncreaseACTH response in Addison's disease versus controls
    Study

    n = 13

    Comparator
    Control subjects
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1 ug/kg · iv · single doseAs given in this study (human).

    Source sentences

    Summary
    Patients with Addison's disease on therapy showed a significantly higher ACTH response to GHRP-6 when compared to controls.
    1 context sentence
    Summary · context
    To further clarify this hypothesis, we studied the effect of GHRP-6 (1 ug/kg, iv) on ACTH and F release in patients with Addison's disease (no.=6) during replacement therapy and after 72 h of glucocorticoid withdrawal.
  2. 02HumanNon-randomized trialEfficacy outcome

    In control subjects, GHRP‑6 increased ACTH, from 2.9 to a peak of 4.7 pmol/l.

    In plain wordsIn control people, GHRP‑6 raised ACTH, a pituitary stress hormone.

    Peptide
    GHRP-6
    Outcome
    IncreaseACTH response in control subjects
    Study

    n = 7

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1 ug/kg · iv · single doseAs given in this study (human).

    Measurements

    ACTH baseline
    2.9 pmol/l
    controls
    ACTH peak
    4.7 pmol/l
    controls

    Source sentences

    Summary
    In control subjects, ACTH values (pmol/l; mean +/- SE) increased from 2.9 +/- 0.8 to 4.7 +/- 1.4 (peak).
    2 context sentences
    Summary · context
    Seven controls were also submitted to a single GHRP-6 test.
    Summary · context
    To further clarify this hypothesis, we studied the effect of GHRP-6 (1 ug/kg, iv) on ACTH and F release in patients with Addison's disease (no.=6) during replacement therapy and after 72 h of glucocorticoid withdrawal.
  3. 03HumanNon-randomized trialEfficacy outcome

    In control subjects, GHRP‑6 increased cortisol, from 257.0 to 367.0 nmol/l.

    In plain wordsIn control people, GHRP‑6 raised cortisol, a stress hormone.

    Peptide
    GHRP-6
    Outcome
    IncreaseCortisol response in control subjects
    Study

    n = 7

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1 ug/kg · iv · single doseAs given in this study (human).

    Measurements

    Cortisol baseline
    257 nmol/l
    controls
    Cortisol after GHRP-6
    367 nmol/l
    controls

    Source sentences

    Summary
    F (nmol/l) values increased from 257.0 +/- 42.9 to 367.0 +/- 50.8.
    2 context sentences
    Summary · context
    Seven controls were also submitted to a single GHRP-6 test.
    Summary · context
    To further clarify this hypothesis, we studied the effect of GHRP-6 (1 ug/kg, iv) on ACTH and F release in patients with Addison's disease (no.=6) during replacement therapy and after 72 h of glucocorticoid withdrawal.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with Addison's disease on glucocorticoid replacement, GHRP‑6 increased ACTH from 38.1 to 174.9 pmol/l.

    In plain wordsIn people with Addison's disease on replacement treatment, GHRP‑6 raised ACTH.

    Peptide
    GHRP-6
    Outcome
    IncreaseACTH response in Addison's disease on replacement
    Study

    n = 6

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1 ug/kg · iv · single doseAs given in this study (human).

    Measurements

    ACTH baseline
    38.1 pmol/l
    Addison's disease on replacement
    ACTH after GHRP-6
    174.9 pmol/l
    Addison's disease on replacement

    Source sentences

    Summary
    In patients with Addison's disease there was an increase in ACTH levels from 38.1 +/- 17.1 to 174.9 +/- 79.4 after GHRP-6 administration.
    1 context sentence
    Summary · context
    To further clarify this hypothesis, we studied the effect of GHRP-6 (1 ug/kg, iv) on ACTH and F release in patients with Addison's disease (no.=6) during replacement therapy and after 72 h of glucocorticoid withdrawal.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with Addison's disease after 72 h of glucocorticoid withdrawal, GHRP‑6 produced only a trend toward an increase in ACTH (p=0.053).

    In plain wordsIn people with Addison's disease after stopping steroid replacement for 72 hours, GHRP‑6 showed only a trend toward higher ACTH.

    Peptide
    GHRP-6
    Outcome
    No significant changeACTH response after 72 h glucocorticoid withdrawal
    Study

    n = 6

    Comparator
    Replacement therapy
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1 ug/kg · iv · single doseAs given in this study (human).

    Measurements

    p value
    0.053
    ACTH after GHRP-6, after withdrawal

    Source sentences

    Summary
    After 72 h withdrawal of glucocorticoid, there was an increase in basal ACTH values (191.2 +/- 97.3), and a trend toward an increase in ACTH levels after GHRP-6 (p=0.053).
    1 context sentence
    Summary · context
    To further clarify this hypothesis, we studied the effect of GHRP-6 (1 ug/kg, iv) on ACTH and F release in patients with Addison's disease (no.=6) during replacement therapy and after 72 h of glucocorticoid withdrawal.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with Addison's disease, the enhanced ACTH responsiveness to GHRP‑6 was not maintained after 72 h of glucocorticoid withdrawal.

    In plain wordsIn people with Addison's disease, the stronger ACTH response to GHRP‑6 was no longer seen after 72 hours without steroid replacement.

    Peptide
    GHRP-6
    Outcome
    DecreaseEnhanced ACTH responsiveness after glucocorticoid withdrawal
    Study

    n = 6

    Comparator
    Replacement therapy
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1 ug/kg · iv · single doseAs given in this study (human).

    Source sentences

    Summary
    After 72 h glucocorticoid withdrawal, this enhanced responsiveness is not maintained.
    1 context sentence
    Summary · context
    To further clarify this hypothesis, we studied the effect of GHRP-6 (1 ug/kg, iv) on ACTH and F release in patients with Addison's disease (no.=6) during replacement therapy and after 72 h of glucocorticoid withdrawal.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.